What were Delta-Fly Pharma,Inc.'s latest financial results?

Delta-Fly Pharma,Inc. (4598.T) reported its latest results in an earnings disclosure filed with the Tokyo Stock Exchange. The full English translation is in the article above.

Where can I read Delta-Fly Pharma,Inc.'s earnings disclosure in English?

Pulse News Wire provides real-time English translations of Delta-Fly Pharma,Inc.'s TDNet filings, including this earnings report.

How quickly are Delta-Fly Pharma,Inc.'s TSE filings translated into English?

Pulse News Wire translates Tokyo Stock Exchange disclosures within minutes of filing, covering all 4,436 listed companies including Delta-Fly Pharma,Inc..

| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Delta-Fly Pharma,Inc. Reports Earnings Results

Source disclosure: February 13, 2026 Delta-Fly Pharma,Inc. [4598.T] TOKYO, Feb 19 (Pulse News Wire) – Delta-Fly Pharma,Inc. (4598.T) reported consolidated results for Q3 FY2026 (ending March 2026). Operating profit was ¥-1234 million. net profit was ¥-1248 million. Total assets stood at ¥326 million with an equity ratio of 62.9%. For the next fiscal year, the company forecasts revenue of ¥1.50 billion. AI-translated content. 🟢 Confidence: High See terms • Original filing

Source disclosure: February 13, 2026

Delta-Fly Pharma,Inc. [4598.T]

TOKYO, Feb 19 (Pulse News Wire) – Delta-Fly Pharma,Inc. (4598.T) reported consolidated results for Q3 FY2026 (ending March 2026).

9%. For the next fiscal year, the company forecasts 50 billion.

Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.

AI-translated content. 🟢 Confidence: High See terms • Original filing

💬 Help us improve translation quality

Notice any errors in this article? Let us know with one click.

🎁 Report 3+ errors with your email and get a free month of premium access

Delta-Fly Pharma,Inc. Reports Earnings Results

Related Disclosures